BioArray News GenomeWeb News Premium Content Existing subscribers login here. New to BioArray News? For a trial subscription click here.

Roche Official Says Firm Bought NimbleGen
To Complement 454; Affy Deal Unaffected

[June 26, 2007]

By Justin Petrone

While Roche has provided limited details on how NimbleGen will be integrated into the company, it has maintained that NimbleGen will remain an autonomous business unit of Roche Diagnostics and will continue to operate out of its facilities in Madison, Wis., and Reykjavik, Iceland. The firm is also expected to maintain its branding, like 454 Life Sciences has done so far.

Login | Subscribe